IPO Date: Jan 29 to Jan 31 2025
Listing Date: Feb 4 2025
Our Company proposes to utilise the Net Proceeds from the Fresh Issue towards funding of the following objects:
1. Repayment/prepayment, in part or full, of certain of our borrowings; and
2. General corporate purposes and unidentified inorganic acquisition
6th Floor, Menon Eternity 1st Main Road, Austin Nagar Alwarpet
Chennai
Tamil Nadu
600018
044-43787777
info@dragarwal.com
www.dragarwals.co.in
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
In accordance with the provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Edelweiss Financial Services has informed that Infomerics Valuation and Rating vide their letter dated November 12, 2026, has assigned the rating of ‘IVR AA-/ Stable’ to the proposed Non-convertible Debentures programme of Rs. 100 crores to ECap Equities, a wholly owned subsidiary of the company. This rating is based on a consolidated view of Edelweiss Financial Services Limited (EFSL) and its subsidiaries and considers the close operational, financial and managerial linkages between the Company and its subsidiaries.
Pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’), Yashhtej Industries (India) has informed that the Board of Directors of the Company in their meeting held on Friday, November 13, 2026, at the Registered Office of the Company situated at Plot No. D-73/1, Additional MIDC, Latur-413512, Maharashtra, India, has transacted the following main business: 1) Considered and approved the Unaudited Standalone Financial Results for the Half Year ended September 30, 2026, along with the Statement of Assets and Liabilities and Cash Flow Statement for the Half Year ended September 30, 2026; A copy of the Financial Results along with the Auditor’s Limited Review Report is enclosed as Annexure-A. 2). Approved the appointment of Krupa Mayankkumar Gandhi (Membership No. A82371) as the Company Secretary and Compliance Officer of the Company with effect from November 13, 2026. The details as required under Regulation 30 read with SEBI Master Circular HO/49/14/14(7)2025-CFDPOD2/1/3762/2026 dated January 30, 2026 is enclosed as Annexure-B. The Board Meeting commenced at 12:15 PM and concluded at 3:00 PM.
The above information is a part of company’s filings submitted to BSE.
No Records Found
The issue size of Dr. Agarwal's Health Care Ltd. IPO is ₹2044.70 - 2151.75 crore.
The Dr. Agarwal's Health Care Ltd. IPO opens for subscription on 2025-01-29 and closes on 2025-01-31.
The price range of Dr. Agarwal's Health Care Ltd. IPO is ₹382.00 to ₹402.00.
The lot size of Dr. Agarwal's Health Care Ltd. IPO is 35 shares.
The registrar of Dr. Agarwal's Health Care Ltd. IPO is K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.).
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.